Mimedx Group, Inc · NASDAQ:MDXG
Mimedx — Investor Presentation (January 2026)
22 slides from Mimedx's investor presentation, Jan 12, 2026
Slide 1: Investor Presentation January 2026
Investor Presentation January 2026
Slide 2: Disclaimer & Cautionary Statements
Disclaimer & Cautionary Statements This presentation and our earnings call includes forward-looking statements. Forward-looking statements are subject to risks and uncertainties, and the Company cautions investors against placing undue reliance on such statements. Actual results may differ materiall
Slide 3: Reconciliation of Non-GAAP Measures
Reconciliation of Non-GAAP Measures | 3 | In addition to our GAAP results, we provide certain non-GAAP measures including Adjusted EBITDA, related margins, Free Cash Flow, Adjusted Gross Profit, Adjusted Gross Margin, Adjusted Net Income and Adjusted EPS. • Adjusted EBITDA consists of GAAP net incom
Slide 4: Investment Rationale
Investment Rationale | 4 | Addressing large & expanding markets in Wound and Surgical Attractive opportunities to expand growth through M&A Key competitive advantages with innovative products, extensive IP, proprietary technologies and expansive sales infrastructure Strong balance sheet and cash flo
Slide 5: MIMEDX – A Pioneer & Leader Delivering Healing Solutions in Healthcare
MIMEDX – A Pioneer & Leader Delivering Healing Solutions in Healthcare | 5 | At MIMEDX, our vision is to be the leading global provider of healing solutions through relentless innovation to restore quality of life. AN INDUSTRY PIONEER in Advanced Wound Care with a product offering backed by a compen
Slide 6: Addressing a Large and Unmet Need for Healing Solutions
Addressing a Large and Unmet Need for Healing Solutions 1 - Sen CK, et al. Human Wound and Its Burden: Updated 2025 Compendium of Estimates. Adv Wound Care (New Rochelle). 2025; doi: 10.1177/21621918251359554 2 - Tettelbach WH, et al. Cost-effectiveness of dehydrated human amnion/chorion membrane al
Slide 7: The Patient Journey in Wound Care
The Patient Journey in Wound Care MIMEDX products are available throughout the continuum of care… | 7 | Mohs surgery Burn/Trauma DFU VLU Limb Salvage Dehiscence Acute Wounds Chronic Wounds Complex Wounds Private Offices Nursing Facilities Wound Care Clinics Assisted Living Facilities Ambulatory Surg
Slide 8: Surgical Studies Underway Highlight Product Versatility
Surgical Studies Underway Highlight Product Versatility… | 8 | Generating Clinical Data in Numerous Surgical Disciplines Incorporating Use of MIMEDX Products AMNIOEFFECT in High-Risk Vascular E-Published April 2025 Vascular Published May 2025 Journal of Drugs in Dermatology EPIFIX® in Mohs (HECON) P
Slide 9: Expand Our Opportunities While Reducing Health & Economic Burdens
… And Expand Our Opportunities, While Reducing Health & Economic Burdens Compelling Data Supporting Use of MIMEDX Products in Colorectal Anastomosis Procedures 1) Rennie O, Sharma M, Helwa N. Colorectal anastomotic leakage: a narrative review of definitions, grading systems, and consequences of leak
Slide 10: The Most Comprehensive End-To-End Product Ecosystem
The Most Comprehensive End-To-End Product Ecosystem Leading the field with science, clinical efficacy and a customer and patient-centric go-to-market mindset | 10 | The most studied portfolio of placental products with a growing compendium of published scientific, clinical and health outcome data La
Slide 11: Unmatched peer-reviewed published evidence supporting our product portfolio
The Most Comprehensive End-To-End Product Ecosystem Unmatched peer-reviewed published evidence supporting our product portfolio | 11 | The most studied portfolio of placental products with a growing compendium of published scientific, clinical and health outcome data Broadest commercial payor covera
Slide 12: National footprint with labor and delivery centers to obtain placental tissue
The Most Comprehensive End-To-End Product Ecosystem National footprint with labor and delivery centers to obtain placental tissue | 12 | Consent for Donation Obtained Delivery of Healthy Baby via Caesarean Section Donated Placental Tissues Recovered Tissues Transported to MIMEDX National Network of
Slide 13: Leveraging robust IP portfolio to drive continued innovations
The Most Comprehensive End-To-End Product Ecosystem Leveraging robust IP portfolio, knowhow and expertise to drive continued innovations for Wound & Surgical markets | 13 | New product innovations leading to untapped opportunities for growth, including an increasing footprint in the Surgical market.
Slide 14: MIMEDX Connect practice management portal
The Most Comprehensive End-To-End Product Ecosystem MIMEDX Connect offers a full suite of practice management tools in a single online portal to help customers simplify workflows, maximize efficiency and increase lifetime value of each customer | 14 | A key partner to healthcare professionals with i
Slide 15: Wound Results Driven by Market Dynamics; Poised to Capitalize in ‘26 & Beyond
Wound Results Driven by Market Dynamics; Poised to Capitalize in ‘26 & Beyond | 15 | $0 $50,000 $100,000 $150,000 $200,000 $250,000 $300,000 $0 00 s LTM Wound Performance Q3:22 Q3:23 Q3:24 Q3:25 LTM Wound % of Sales Current / Future Wound Revenue Drivers • New product launches, including CELERA, EME
Slide 16: Growing Surgical Footprint Diversifies & Differentiates Our Business
Growing Surgical Footprint Diversifies & Differentiates Our Business | 16 | Current / Future Surgical Revenue Drivers • Expanding use of AMNIOFIX & AMNIOEFFECT in growing number of Surgical indications • Double-digit growth in our particulate portfolio 2025 • Ongoing clinical efficacy and health out
Slide 17: Financial Highlights
Financial Highlights 1) EBITDA, Adjusted EBITDA, related margins and Free Cash Flow are non-GAAP financial measures. See our Earnings Release for the quarter ended September 30, 2025 for a reconciliation to the nearest GAAP measure. | 17 | Quarterly Net Cash Balance $393MM +15% year-over-year $124MM
Slide 18: Expect CMS Reform to Transform Wound Care Landscape in 2026
• Meaningful reduction in Medicare spend, due to new payment rate significantly below 2025 and prior ASP+6% market rates for many skin substitutes that were previously reimbursed in excess of $5,000/sq.cm • Expected shift in patient volume from mobile and home-based care settings back to hospital ou
Slide 19: Execution of Strategic Priorities Position Business for Long-Term Success
Execution of Strategic Priorities Position Business for Long-Term Success | 19 | Innovate & Diversify Product Portfolio to Maximize Growth Develop & Deploy Programs to Expand Surgical Footprint Enhance Customer Intimacy Surgical uptake continues to be very strong, with Q3 growth of 26% AMNIOFIX & AM
Slide 20: Experienced, Skillful Leadership Team Executing Strategy
Experienced, Skillful Leadership Team Executing Strategy Prior Roles Include: Management Team with Track Record of Success in MedTech Joe Capper Chief Executive Officer Doug Rice Chief Financial Officer Butch Hulse Chief Administrative Officer & General Counsel Kim Moller Chief Commercial Officer Ri
Slide 21: Summary
Summary | 21 | Addressing large & expanding markets Attractive opportunities to expand growth Key competitive advantages Strong balance sheet and cash flow generation Experienced leadership team
Slide 22: Thank You
THANK YOU MIMEDX 1775 West Oak Commons Ct. Marietta, GA 30062 888.543.1917 | 770.651.9100 | 22 |